… or why STN is going to fail. DGENE and USGENE recently introduced an option to limit sequence searches (BLAST) by % match. But I think it might just be too little to late for them. For too long now STN has enjoyed the benefits of monopoly in the field of patent sequence searching. However, a new entrant in the domain threatens not only to end the monopoly but might also bring an end to STNs business in this field. GenomeQuest has quietly, but steadily has become the tool of choice for patent information searchers. More and more people, including some patent offices, have started accepting it as a standard. So why exactly is this happening?? Sequence searching on STN[…]

The inevitable has happened. Google has finally launched a patent search engine. You can check it out at http://www.google.com/patents For long I had wished that Google gives a better patent search option, and it has finally happened. Complete with advanced search options including assignee, inventor, IPC classes, and date limitations it is gonna be one heck of a tool for prior art search. I hope it does normal language search more effectively than concept search on PatentCafe. Though the jurisdiction coverage is currently limited to granted US patents only, I am sure it would not be long before it adds other major Patent Offices like EPO and WIPO to it and published applications/pre-grant publications. I sure see some competition for[…]

Pfizer, world’s largest drug maker, got hammered badly in the NYSE on Monday following the disclosure that it had pulled the plug on its “to-be” blockbuster drug, torcetrapib. The stock lost 11% of its market value and wiped out USD 21 bn off its market cap. Though some might consider this as excessive, this just goes to show what one drug can do to a company’s fortune. Pfizer banks on Lipitor for almost a quarter of its annual USD 51 bn sales and a higher percentage of its profits. With Lipitor patent coverage expiring in 2011 (thanks to Ranbaxy), torcetrapib was supposed to take its place and drive the company’s growth and profits. Pfizer had spent over a billion USD[…]

Only recently the USPTO suggested a peer review mechanism to ensure that bad patents are minimized. Wikipatents, launched on August 28th, aims to contribute to “the US patent system by commenting on issued patents and, soon, pending patent applications.” This comes on the heels of the IBM, Red Hat, Microsoft and Hewlett-Packard backed Community Patent Review plan of the New York Law School scheduled for a debut early next year. A Web 2.0 website, complete with AJAX and Digg options, Wikipatents, provides you with entire patent data in HTML/PDF format and allows a registered user to write a title and abstract in a layman’s language. It also allows users to vote on cited references, add comments to existing ones and[…]